Rusfertide

Protagonist Therapeutics, with strong financial health and a 95% return over the past year, is advancing its lead candidate, rusfertide, in Phase 3 trials for polycythemia vera. Strategic partnerships with Johnson & Johnson and Takeda support pipeline growth. The company's robust cash position sustains operations through 2027, with a diverse pipeline including PN-881 for psoriasis. Key clinical trial outcomes will significantly impact its market position and growth potential.

Takeda's late-stage pipeline includes six programs with peak revenue potential of $10B - $20B, with Phase 3 data readouts expected in 2025 for Oveporexton, Zasocitinib, and Rusfertide. Regulatory filings for these drugs are planned for FY2025-2026, with additional filings anticipated through FY2029.

Rusfertide, a hepcidin mimetic, showed durable hematocrit control, reduced phlebotomy use, and improved patient outcomes in polycythemia vera patients over 2.5 years in the REVIVE Phase 2 study. Rusfertide was well-tolerated, with mild to moderate adverse events.

Rusfertide, a hepcidin mimetic, demonstrated durable hematocrit control (<45%) and decreased phlebotomy use in polycythemia vera patients for over 2.5 years, with long-term tolerability and improved patient-reported outcomes, according to final data from the Phase 2 REVIVE study presented at the 66th ASH Annual Meeting.

On Sept 30, 2024, Biotechnology Value Fund L P sold 2,793,521 shares of Protagonist Therapeutics Inc (PTGX), reducing its holdings to 2,970,427 shares at $45/share. PTGX, a clinical-stage biopharmaceutical company, has a market cap of $2.45B and a stock price of $41.04, down 8.8% since the transaction. The sale adjusted BVF L P's PTGX exposure to 4.90% of its portfolio, reflecting strategic portfolio management.

Protagonist Therapeutics to present final Phase 2 REVIVE study data on rusfertide for polycythemia vera at the 66th ASH Annual Meeting in San Diego, December 7-10, 2024.

Takeda Pharmaceutical reports 5% revenue growth in H1 FY24, driven by Growth & Launch portfolio, despite VYVANSE sales decline. The company raises full-year guidance, with core operating profit margin at 30.2%, and focuses on late-stage pipeline investments. Key highlights include ENTYVIO's double-digit growth and Phase 3 trials for TAK-861 and mezagitamab.